Search
Bradanicline
go.drugbank.com/drugs/DB06090InvestigationalBradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders.
Mitumomab
go.drugbank.com/drugs/DB06462ExperimentalMitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.
Idronoxil
go.drugbank.com/drugs/DB04915InvestigationalIt belongs to the family of drugs called signal transduction inhibitors.
Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate
go.drugbank.com/drugs/DB02937ExperimentalAdenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem]
Emerfetamab
go.drugbank.com/drugs/DB18474InvestigationalEmerfetamab is a bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor.
Apelin
go.drugbank.com/drugs/DB18909InvestigationalApelin is under investigation in clinical trial NCT03449251 (A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin).
Ansofaxine
go.drugbank.com/drugs/DB15052InvestigationalAnsofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).
Zimlovisertib
go.drugbank.com/drugs/DB15143InvestigationalPF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Quilizumab
go.drugbank.com/drugs/DB15176InvestigationalQuilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
Ziritaxestat
go.drugbank.com/drugs/DB15403InvestigationalZiritaxestat is under investigation in clinical trial NCT03798366 (A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis).